Tapan M Kadia

Trials

Studies that name Tapan M Kadia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:31 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT05010772 · Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

  M.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
• Ph1
  NCT04874480 · Tegavivint for the Treatment of Relapsed or Refractory Leukemia

  M.D. Anderson Cancer Center · active not recruiting · Recurrent Leukemia, Refractory Leukemia · principal investigator
• Ph1/Ph2
  NCT04848974 · Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

  M.D. Anderson Cancer Center · completed · Secondary Acute Myeloid Leukemia · principal investigator
• Ph1
  NCT04526795 · Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

  M.D. Anderson Cancer Center · terminated · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia · principal investigator
• Ph2
  NCT04062266 · AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

  M.D. Anderson Cancer Center · terminated · Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder · principal investigator
• Ph1
  NCT03989466 · Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

  M.D. Anderson Cancer Center · completed · Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia · principal investigator
• Ph1
  NCT03773393 · A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

  Cellenkos, Inc. · active not recruiting · Bone Marrow Disease · principal investigator
• Ph2
  NCT03629171 · Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  M.D. Anderson Cancer Center · recruiting · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT03586609 · Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

  M.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
• Ph1
  NCT03132454 · Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

  M.D. Anderson Cancer Center · active not recruiting · Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia · principal investigator
• Ph2
  NCT02532231 · Nivolumab in AML in Remission at High Risk for Relapse

  M.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Blasts Under 10 Percent of Bone Marrow Nucleated Cells · principal investigator
• Ph1
  NCT02530034 · Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

  M.D. Anderson Cancer Center · terminated · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
• Ph2
  NCT02126553 · Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

  M.D. Anderson Cancer Center · completed · Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT02115295 · Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

  M.D. Anderson Cancer Center · recruiting · Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
• Ph2
  NCT01624805 · Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  M.D. Anderson Cancer Center · recruiting · Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT00806598 · Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

  M.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Aplastic Anemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2015 to 2026
  Named on NCT02532231
• SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
  P50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Elizabeth J Shpall · fiscal years 2015 to 2023
  Named on NCT02530034